MC4R — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL47196	0.78	20/20
SCHEMBL47227	0.78	20/20
SCHEMBL47218	0.78	20/20
SCHEMBL47261	0.76	20/20
SCHEMBL47107	0.74	20/20
SCHEMBL47145	0.72	20/20
SCHEMBL47114	0.69	20/20
SCHEMBL47093	0.69	20/20
SCHEMBL47136	0.69	20/20
SCHEMBL47112	0.67	20/20
SCHEMBL47197	0.67	20/20
SCHEMBL47198	0.67	20/20
SCHEMBL47138	0.66	20/20
SCHEMBL47117	0.65	20/20
SCHEMBL47121	0.65	20/20
SCHEMBL47135	0.65	20/20
SCHEMBL46876	0.64	20/20
SCHEMBL46980	0.63	20/20
SCHEMBL47263	0.63	20/20
SCHEMBL46983	0.63	20/20

Clinical trials — most relevant to MC4R by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Young Adults With Early-onset Obesity Treated With Semaglutide	PHASE4	COMPLETED
Long Term Extension Trial of Setmelanotide	PHASE2/PHASE3	COMPLETED
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity	PHASE3	COMPLETED
Open-Label Extension Study of Setmelanotide	PHASE3	ENROLLING_BY_INVITATION
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes	PHASE3	RECRUITING
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway	PHASE3	ACTIVE_NOT_RECRUITING
Atomoxetine in Melanocortin Obesity Syndrome	PHASE2	NOT_YET_RECRUITING
DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway	PHASE2	COMPLETED
Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions	PHASE2	COMPLETED
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity	PHASE2	COMPLETED
Theophylline Treatment for Pseudohypoparathyroidism	PHASE2	ACTIVE_NOT_RECRUITING
ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)	PHASE2	COMPLETED
Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)	PHASE2	NOT_YET_RECRUITING
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment	PHASE1/PHASE2	RECRUITING
Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity	PHASE2	COMPLETED
Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo	PHASE2	ACTIVE_NOT_RECRUITING
Effects of RM-493 on Energy Expenditure in Obese Individuals	PHASE1	COMPLETED
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers	PHASE1	COMPLETED
Retrospective Evaluation of Melanocortin Receptor 4 Polymorphisms in Patients With GBM Treated With Radiochemotherapy	nan	COMPLETED
Vanderbilt Childhood Obesity Registry	nan	COMPLETED
Melanocortin 4 Receptor Mutations and Obesity-associated Diseases	nan	COMPLETED
The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry	nan	COMPLETED
Brain-Derived Neurotrophic Factor in Obesity and Brain Function	nan	COMPLETED
Rare Obesity Cohorts With Food Behavioral Disorders : Better Diagnosis for Better Treatment	nan	RECRUITING
Genetic Research of Monogenic Obesity in a Pediatric Cohort With Severe and Early Onset Obesity (GENOBE)	nan	UNKNOWN
Assessing Obesity Related Risk Factors in Adult Population: A Genetic and Behavioral Study	nan	ENROLLING_BY_INVITATION
SEMASEARCH, Retrospective/Prospective Cohort Nested at ATUc/AP2 WEGOVY®	nan	COMPLETED
FACILITY: Feeding the fAmiLy: the Intergenerational approaCh to fIght obesiTY	nan	UNKNOWN
Eating Behavior in Children	nan	COMPLETED
Effect of Vestibular Stimulation on Fat Consumption and Energy Expenditure as Assessed Using Indirect Calorimetry	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MC4R binder may also engage these)

Protein	Name	Similarity
O97504	—	1.000	O97504 →
P70596	—	1.000	P70596 →
P56450	—	1.000	P56450 →
Q8HXX3	—	1.000	Q8HXX3 →
Q0Z8I9	—	1.000	Q0Z8I9 →
Q9GLJ8	—	1.000	Q9GLJ8 →
P35345	—	1.000	P35345 →
P33033	—	1.000	P33033 →
P32244	—	1.000	P32244 →
P56451	—	1.000	P56451 →
P41149	—	1.000	P41149 →
MC5R	Melanocortin receptor 5	1.000	landscape →
MC3R	Melanocortin receptor 3	1.000	landscape →
Q9TU77	—	1.000	Q9TU77 →
P70115	—	1.000	P70115 →
P41983	—	1.000	P41983 →
B0V1P1	—	1.000	B0V1P1 →
Q9TT23	—	0.999	Q9TT23 →
MC2R	Adrenocorticotropic hormone receptor	0.997	landscape →
P34974	—	0.996	P34974 →
Q9MZV8	—	0.995	Q9MZV8 →
Q64326	—	0.995	Q64326 →
Q8HYN8	—	0.992	Q8HYN8 →
Q9Z1S9	—	0.992	Q9Z1S9 →
Q01727	—	0.987	Q01727 →
Q80SS9	—	0.986	Q80SS9 →
Q8BX79	—	0.986	Q8BX79 →
GPR52	G-protein coupled receptor 52	0.986	landscape →
P0C5J4	—	0.985	P0C5J4 →
Q80SZ5	—	0.984	Q80SZ5 →